POWERED BY BIOHM
LIVE

Serial Number

87757230

Owner

PathoBiome LLC

Attorney

Lisa C. Pavento

First Use Date

Feb 17, 2022

Filing Date

Jan 16, 2018

Add to watchlist:

No watchlists yet
View on USPTO

POWERED BY BIOHM Trademark

Serial Number: 87757230 • Registration: 6707595

POWERED BY BIOHM is a trademark filed by PathoBiome LLC on January 16, 2018. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

PathoBiome LLC (23 trademarks)

Suite 4500
Cleveland, OH 44115

Entity Type: 16

BIOHM HEALTH INC. (51 trademarks)

425 LITERARY ROAD
CLEVELAND, OH 44113

Entity Type: 99

BIOHM HEALTH LLC (23 trademarks)

CLEVELAND, OH 44113

Entity Type: 16

Trademark Details

Filing Date

January 16, 2018

Registration Date

April 19, 2022

First Use Anywhere

February 17, 2022

First Use in Commerce

February 17, 2022

Published for Opposition

December 25, 2018

Goods & Services

Probiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; nutritional supplements for human consumption providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; herbal supplements for general health and well-being, namely, in powder, tablet, liquid, capsule or spray form; nutritional supplements, namely, probiotic compositions in the nature of a vaginal probiotic for the treatment and prevention of bacterial and fungal vaginal infection; nutraceuticals for the treatment and prevention of bacterial vaginosis, vaginal discharge and odors, for preventing the growth of undesirable micro-organisms that can cause vaginal discharge and odor, killing bacteria that cause bacterial vaginosis, and for maintaining a desirable microflora in the vaginal cavity; micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism; pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and crohn's disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; microbial and biological preparations for medical use for improving the physical well-being of humans, namely, reducing inflammation and pain; dietary supplements for medical use, and baby food, all the above containing preparations and products resulting from the processing of microorganisms, particularly metabolites obtained from the processing of probiotic bacterial cultures; probiotic and nutritional and dietary supplements; antifungal preparations; antifungal creams for medical use; vaginal antifungal preparations; fungal and bacterial probiotic supplements, and nutritional supplement for digestive health; nutritional supplement for combating digestive disorders such as Crohn's Disease, ulcerative colitis and irritable bowel syndrome; beverages containing probiotic compositions for use as a nutritional supplement; food supplements containing probiotic compositions; human food supplements products containing probiotic compositions; animal food products containing probiotic compositions, namely, probiotic animal feed; dietary supplement drink mixes, namely, probiotic compositions in the form of mixes to added to beverages; dietary supplements in the nature of probiotic compositions for mixing with cereal

Food products containing probiotic compositions, namely, probiotic bacteria and probiotic bacterial cultures for use as a food additive for food manufacturing; human food products containing probiotic compositions, namely, probiotic bacteria and probiotic bacterial cultures for use as a food additive for food manufacturing; animal food products containing probiotic compositions, namely, nutritional additives for use in manufacturing animal feed

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 21, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 21, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 21, 2025 REAP
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Feb 15, 2023 ASGN
REGISTERED-PRINCIPAL REGISTER
Apr 19, 2022 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Mar 15, 2022 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Mar 13, 2022 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Mar 1, 2022 SUPC
USE AMENDMENT FILED
Feb 18, 2022 IUAF
TEAS STATEMENT OF USE RECEIVED
Feb 18, 2022 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 10, 2021 EXRA
SOU EXTENSION 5 GRANTED
Aug 9, 2021 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 6, 2021 AITU
SOU EXTENSION 5 FILED
Jul 28, 2021 EXT5
SOU TEAS EXTENSION RECEIVED
Jul 28, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 17, 2021 EXRA
SOU EXTENSION 4 GRANTED
Feb 15, 2021 EX4G
SOU EXTENSION 4 FILED
Feb 15, 2021 EXT4
SOU TEAS EXTENSION RECEIVED
Feb 15, 2021 EEXT
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 5, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 5, 2020 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 5, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 5, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 5, 2020 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 21, 2020 EXRA
SOU EXTENSION 3 GRANTED
Aug 19, 2020 EX3G
SOU EXTENSION 3 FILED
Aug 19, 2020 EXT3
SOU TEAS EXTENSION RECEIVED
Aug 19, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 28, 2020 EXRA
SOU EXTENSION 2 GRANTED
Feb 27, 2020 EX2G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 27, 2020 AITU
SOU EXTENSION 2 FILED
Feb 18, 2020 EXT2
SOU TEAS EXTENSION RECEIVED
Feb 18, 2020 EEXT
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 18, 2020 TCCA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 20, 2019 EXRA
SOU EXTENSION 1 GRANTED
Aug 16, 2019 EX1G
SOU EXTENSION 1 FILED
Aug 16, 2019 EXT1
SOU TEAS EXTENSION RECEIVED
Aug 16, 2019 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 19, 2019 NOAM
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jan 30, 2019 ASGN
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 25, 2018 NPUB
PUBLISHED FOR OPPOSITION
Dec 25, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 5, 2018 NONP
ASSIGNED TO LIE
Nov 12, 2018 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 28, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 26, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 26, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 26, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 30, 2018 GNRN
NON-FINAL ACTION E-MAILED
Apr 30, 2018 GNRT
NON-FINAL ACTION WRITTEN
Apr 30, 2018 CNRT
ASSIGNED TO EXAMINER
Apr 26, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 29, 2018 NWOS